Delving into the Latest Updates on AstraZeneca Pty Ltd. with Synapse

Overview

Tags

Other Diseases

Endocrinology and Metabolic Disease

Neoplasms

Small molecule drug

Monoclonal antibody

Prophylactic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	8
Neoplasms	7
Nervous System Diseases	6
Infectious Diseases	6
Hemic and Lymphatic Diseases	5
Immune System Diseases	5

Top 5 Drug Type	Count

Small molecule drug	10
Monoclonal antibody	4
Antibody drug conjugate (ADC)	1
Recombinant vector vaccine	1
Prophylactic vaccine	1

Top 5 Target	Count

SARS-CoV-2 S protein	3
BTK(Tyrosine-protein kinase BTK)	1
Proton pump	1
AT1R(Angiotensin II Receptor Type 1)	1
Akt-1 x Akt-2 x Akt-3	1

Twenty seven adults and 20 children with previously diagnosed stable asthma, using a salbutamol pressurized metered dose inhaler (P-MDI) and living in Cairns, Townsville and Southport, Queensland, Australia participated in a randomized, open-label cross-over comparison of terbutaline administered via Turbuhaler and salbutamol administered via P-MDI. The aim of the study was to compare the clinical effectiveness and patient acceptance of the two treatments in hot, humid regions. Terbutaline was administered via Turbuhaler and salbutamol via P-MDI on at least two occasions per day during each four week treatment period. Spirometry was performed at the start of the study, after the two week run-in and at the end of each treatment period. Patients used diary cards to record morning and evening peak expiratory flows, daily symptom scores and daily intake of beta 2 agonist medication. At the end of the study, patients answered a treatment preference question. Forty six patients completed the study. No statistically significant differences were observed between the two treatments in peak expiratory flow, change in morning peak expiratory flow pre- and post-beta-agonist, daily symptom scores, diurnal variability and spirometry. Forty four percent of patients preferred the terbutaline Turbuhaler and 39% preferred salbutamol P-MDI. Both agents were similarly tolerated. Terbutaline delivered by Turbuhaler is as clinically effective as salbutamol delivered by P-MDI in patients with asthma living in hot, humid regions.

100 Deals associated with AstraZeneca Pty Ltd.

Login to view more data

100 Translational Medicine associated with AstraZeneca Pty Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

16

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Candesartan Cilexetil ( AT1R )	Heart Failure More	Approved
Tremelimumab ( CTLA4 )	Unresectable Hepatocellular Carcinoma More	Approved
COVID-19 Vaccine (ChAdOx1-S [recombinant])(AstraZeneca Plc) ( SARS-CoV-2 S protein )	COVID-19 More	Approved
Cilgavimab/Tixagevimab ( SARS-CoV-2 S protein )	COVID-19 More	Approved
Andexanet alfa ( factor Xa )	Hemorrhage More	Approved